Covalon Wins Health Canada Approval
Covalon Technologies has received approval from the therapeutic product directorate at Health Canada to begin marketing the corporation’s proprietary products, Biostep collagen matrix dressing, and Biostep Ag collagen matrix dressing with silver.
According to the company, the products are advanced wound care dressings that create a moist wound healing environment, deactivate harmful wound proteases and promote tissue growth in chronic wounds, which affect an increasingly large number of patients and have a serious impact on their quality of life.
The products will be marketed by Smith & Nephew under the terms of exclusive worldwide sales, marketing and distribution agreement announced in 2007.
Frank DiCosmo, president and CEO of Covalon, said: “Clinicians participating at a clinical in-market study indicated that these new collagen dressings facilitate granulation and epidermal migration as the majority of patients experienced a reduction in wound areas and an increase in the percentage of epithelial tissue over time.”